Zacks Small Cap Increases Earnings Estimates for Cingulate

Cingulate Inc. (NASDAQ:CING) – Investment analysts at Zacks Small Cap increased their FY2024 earnings estimates for shares of Cingulate in a research report issued on Tuesday, November 12th. Zacks Small Cap analyst J. Vandermosten now anticipates that the company will post earnings of ($9.50) per share for the year, up from their prior forecast of ($16.00). The consensus estimate for Cingulate’s current full-year earnings is ($12.51) per share. Zacks Small Cap also issued estimates for Cingulate’s Q4 2024 earnings at ($1.49) EPS, FY2025 earnings at ($2.33) EPS and FY2026 earnings at ($0.27) EPS.

Cingulate Trading Down 2.5 %

Shares of NASDAQ CING opened at $4.22 on Thursday. The business has a 50 day simple moving average of $4.74 and a 200-day simple moving average of $3.04. Cingulate has a twelve month low of $1.80 and a twelve month high of $152.40.

Cingulate (NASDAQ:CING) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($1.83) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.22) by $0.39.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Cingulate stock. Armistice Capital LLC bought a new stake in Cingulate Inc. (NASDAQ:CING) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 490,000 shares of the company’s stock, valued at approximately $157,000. Armistice Capital LLC owned 6.67% of Cingulate as of its most recent SEC filing. Institutional investors and hedge funds own 41.31% of the company’s stock.

Cingulate Company Profile

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.